Relationship between the increased haemostatic properties of blood platelets and oxidative stress level in multiple sclerosis patients with the secondary progressive stage

Oxidative Medicine and Cellular Longevity

Volumn 2015, Issue , 2015, Pages

  Morel, Agnieszka ^a   Bijak, Michab ^a   Miller, Elhbieta ^b,c   Rywaniak, Joanna ^a   Miller, Sergiusz ^b   Saluk, Joanna ^a,d  

^a UNIVERSITY OF LODZ   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c III General Hospital in Lodz   (Poland)

^d WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOACTIVITY; BLOOD; NEUROLOGY; OXIDATIVE STRESS; PHYSIOLOGICAL MODELS;

AUTOIMMUNE DISEASE; CENTRAL NERVOUS SYSTEMS; CHRONIC DISEASE; CLINICAL COURSE; HEALTHY VOLUNTEERS; MULTIPLE SCLEROSIS; PHYSIOLOGICAL AGONISTS; SCIENTIFIC PAPERS;

PLATELETS;

ADENOSINE DIPHOSPHATE; COLLAGEN; FIBRINOGEN; OXYGEN RADICAL; THROMBIN; HEMOSTATIC AGENT; SUPEROXIDE;

ADULT; ARTICLE; BIOLOGICAL ACTIVITY; CELL ACTIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; EXPANDED DISABILITY STATUS SCALE; FEMALE; HEMOSTASIS; HUMAN; HUMAN CELL; MALE; MULTIPLE SCLEROSIS; OXIDATIVE STRESS; PLATELET REACTIVITY; THROMBOCYTE; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; BLOOD; CASE CONTROL STUDY; DRUG EFFECTS; METABOLISM; MIDDLE AGED; PATHOLOGY; THROMBOCYTE RICH PLASMA;

ADENOSINE DIPHOSPHATE; BLOOD PLATELETS; CASE-CONTROL STUDIES; COLLAGEN; FEMALE; FIBRINOGEN; HEMOSTATICS; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; OXIDATIVE STRESS; PLATELET ADHESIVENESS; PLATELET-RICH PLASMA; SUPEROXIDES; THROMBIN;

EID: 84929358935     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2015/240918     Document Type: Article

References (39)

1. E. Miller, "Multiple sclerosis," in Neurodegenerative Diseases, vol. 724 of Advances in Experimental Medicine and Biology, pp. 222-238, Springer, New York, NY, USA, 2012.
2. A. Gaby, "Multiple sclerosis," Global Advances in Health and Medicine, vol. 2, no. 1, pp. 50-56, 2013.
3. M. Bradl and H. Lassmann, "Progressive multiple sclerosis," Seminars in Immunopathology, vol. 31, no. 4, pp. 455-465, 2009.
4. D. Fitzner and M. Simons, "Chronic progressive multiple sclerosis-pathogenesis of neurodegeneration and therapeutic strategies," Current Neuropharmacology, vol. 8, no. 3, pp. 305-315, 2010.
5. A. Fiorini, T. Koudriavtseva, E. Bucaj et al., "Involvement of oxidative stress in occurrence of relapses in multiple sclerosis: The spectrum of oxidatively modified serum proteins detected by proteomics and redox proteomics analysis," PLoS ONE, vol. 8, no. 6, Article IDe65184, 2013.
6. J. Witherick, A. Wilkins, N. Scolding, and K. Kemp, "Mechanisms of oxidative damage in multiple sclerosis and a cell therapy approach to treatment,"AutoimmuneDiseases, vol. 2011, no. 1, Article ID 164608, 11 pages, 2011.
7. H. Lassmann, J. van Horssen, and D. Mahad, "Progressive multiple sclerosis: Pathology and pathogenesis," Nature Reviews Neurology, vol. 8, no. 11, pp. 647-656, 2012.
8. S. Christensen, D. K. Farkas, L. Pedersen, M. Miret, C. F. Christiansen, and H. T. Sørensen, "Multiple sclerosis and risk of venous thromboembolism: A population-based cohort study," Neuroepidemiology, vol. 38, no. 2, pp. 76-83, 2012.
9. M. H. Han, S.-I. Hwang, D. B. Roy et al., "Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets," Nature, vol. 451, no. 7182, pp. 1076-1081, 2008.
10. B. Engelhardt and R. M. Ransohoff, "The ins and outs of T-lymphocyte trafficking to the CNS: Anatomical sites and molecular mechanisms," Trends in Immunology, vol. 26, no. 9, pp. 485-495, 2005.
11. Z. Li,M.K.Delaney,K.A.O'Brien, and X.Du, "Signaling during platelet adhesion and activation," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 12, pp. 2341-2349, 2010.
12. S. R. Macfarlane, M. J. Seatter, T. Kanke, G. D. Hunter, and R. Plevin, "Proteinase-activated receptors," Pharmacological Reviews, vol. 53, no. 2, pp. 245-282, 2001.
13. C. Lock, G. Hermans, R. Pedotti et al., "Gene-microarray analysis ofmultiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis," Nature Medicine, vol. 8, no. 5, pp. 500-508, 2002.
14. E. Miller, A. Walczak, J. Saluk, M. B. Ponczek, and I. Majsterek, "Oxidative modification of patient's plasma proteins and its role in pathogenesis ofmultiple sclerosis," Clinical Biochemistry, vol. 45, no. 1-2, pp. 26-30, 2012.
15. E.Miller,M.Mrowicka,K.Zolýnski, and J.Kedziora, "Oxidative stress inmultiple sclerosis," PolskiMerkuriusz Lekarski, vol. 162, pp. 499-502, 2009.
16. B. Wachowicz and J. Kustrón, "Effect of cisplatin on lipid peroxidation in pig blood platelets.," Cytobios, vol. 70, no. 280, pp. 41-47, 1992.
17. B. Walkowiak, E. Michalak, W. Koziolkiewicz, and C. S. Cierniewski, "Rapid photometric method for estimation of platelet count in blood plasma or platelet suspension," Thrombosis Research, vol. 56, no. 6, pp. 763-766, 1989.
18. T. Takagi and R. F. Doolittle, "Amino acid sequence of the carboxy-terminal cyanogen bromide peptide of the human fibrinogen α-chain: Homology with the corresponding α-chain peptide and presence in fragment D," Biochimica et Biophysica Acta-Protein Structure, vol. 386, no. 2, pp. 617-622, 1975.
19. B. Olas, J. Saluk-Juszczak, I. Pawlaczyk et al., "Antioxidant and antiaggregatory effects of an extract fromConyza canadensis on blood platelets in vitro," Platelets, vol. 17, no. 6, pp. 354-360, 2006.
20. B. Jahn and G. M. Hansch, "Oxygen radical generation in human platelets: Dependence of 12-lipoxygenase activity and on the glutathione cycle," International Archives of Allergy and Immunology, vol. 93, pp. 73-79, 1990.
21. H. F. Langer, E. Y. Choi, H. Zhou et al., "Platelets contribute to the pathogenesis of experimental autoimmune encephalomyelitis," Circulation Research, vol. 110, no. 9, pp. 1202-1210, 2012.
22. J. Satoh, "Molecular network analysis ofmultiple sclerosis brain lesion proteome," Nihon RinshoMeneki Gakkai kaishi, vol. 4, pp. 182-188, 2010.
23. B. Savage, F.Almus-Jacobs, and Z. M. Ruggeri, "Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow," Cell, vol. 94, no. 5, pp. 657-666, 1998.
24. L. L. Horstman, W. Jy, Y. S. Ahn et al., "Role of platelets in neuroinflammation: A wide-angle perspective," Journal of Neuroinflammation, vol. 7, article 10, 2010.
25. W. A. Sheremata, J. Y. Wenche, L. L. Horstman, J. S. Ahn, J. S. Alexander, and A. Minagar, "Evidence of platelet activation in multiple sclerosis," Journal of Neuroinflammation, vol. 5, article 27, 2008.
26. M. H. F. Klinger and H. Klüter, "Blood platelets are circulating stores for adhesive proteins, inflammatory mediators, and immunoglobulins-role in nonhemolytic transfusion reactions," Infusionsther Transfusionsmed, vol. 26, no. 1, pp. 20-25, 1999.
27. J. Saluk-Juszczak, K. Królewska, and B. Wachowicz, "Response of blood platelets to α-glucan from Saccharomyces cerevisiae," Platelets, vol. 21, no. 1, pp. 37-43, 2010.
28. H. Hamzeh-Cognasse, F. Cognasse, S. Palle et al., "Direct contact of platelets and their released products exert different effects on human dendritic cell maturation," BMC Immunology, vol. 9, article 54, 2008.
29. B. Kuenz, A. Lutterotti,M. Khalil et al., "Plasma levels of soluble adhsion molecules sPECAM-1, sP-selectin and sE-selectin are associated with relapsing/remitting disease course in multiple sclerosis," Journal of Neuroimmunology, vol. 167, pp. 143-149, 2005.
30. L. Callea, M. Arese, A. Orlandini, C. Bargnani, A. Priori, and F. Bussolino, "Platelet activating factor is elevated in cerebral spinal fluid and plasma of patients with relapsing-remitting multiple sclerosis," Journal of Neuroimmunology, vol. 94,no. 1-2, pp. 212-221, 1999.
31. G. Disanto, A. J. Berlanga, A. E. Handel et al., "Heterogeneity in multiple sclerosis: Scratching the surface of a complex disease," AutoimmuneDiseases, vol. 2011,Article ID932351, 11 pages, 2011.
32. L. Bö, T.M. Dawson, S. Wesselingh et al., "Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains," Annals of Neurology, vol. 36, no. 5, pp. 778-786, 1994.
33. J. P. Eiserich, R. P. Patel, andV. B.O'Donnell, "Pathophysiology of nitric oxide and related species: Free radical reactions and modification of biomolecules," Molecular Aspects of Medicine, vol. 19, no. 4-5, pp. 221-357, 1998.
34. M. H. F. Klinger, "Platelets and inflammation," Anatomy and Embryology, vol. 196, no. 1, pp. 1-11, 1997.
35. F. Krötz, H.-Y. Sohn, and U. Pohl, "Reactive oxygen species: Players in the platelet game," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 11, pp. 1988-1996, 2004.
36. M. Gawaz, H. Langer, and A. E.May, "Platelets in inflammation and atherogenesis,"The Journal of Clinical Investigation, vol. 115, no. 12, pp. 3378-3384, 2005.
37. I. Wens, U. Dalgas, E. Stenager, and B. O. Eijnde, "Risk factors related to cardiovascular diseases and the metabolic syndrome in multiple sclerosis-A systematic review," Multiple Sclerosis, vol. 19, no. 12, pp. 1556-1564, 2013.
38. D. J. Mahad, I. Ziabreva, G. Campbell et al., "Mitochondrial changes within axons in multiple sclerosis," Brain, vol. 132, no. 5, pp. 1161-1174, 2009.
39. M. E. Witte, B. O. Lars, R. J. Rodenburg et al., "Enhanced number and activity of mitochondria in multiple sclerosis lesions," The Journal of Pathology, vol. 219, no. 2, pp. 193-204, 2009.